4.5 Article

Industry Payments to Practicing US Rheumatologists, 2014-2019

Journal

ARTHRITIS & RHEUMATOLOGY
Volume 73, Issue 11, Pages 2138-2144

Publisher

WILEY
DOI: 10.1002/art.41896

Keywords

-

Categories

Funding

  1. Rheumatology Research Foundation
  2. CDC, a Rheumatology Research Foundation Scientist Development award
  3. Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery
  4. Women's Health Career Enhancement award
  5. Eaton Family Career Development Award

Ask authors/readers for more resources

This study investigated the nature, quantity, and geographic distribution of payments from the pharmaceutical industry to US rheumatologists. Results showed that the majority of rheumatologists received less than $5,000, while a small number received over $100,000 each, accounting for a large portion of the total payments. The value of industry payments increased over time, and male rheumatologists received significantly higher payments than female rheumatologists.
Objective Payments from the pharmaceutical industry to practicing physicians may influence prescribing behavior. This study was undertaken to investigate the nature, quantity, and geographic distribution of payments to US rheumatologists. Methods General payments from industry sponsors to US rheumatologists from 2014 to 2019 were extracted from the Centers for Medicare and Medicaid Services Open Payments database. Gender was identified by linking physicians to the National Plan and Provider Enumeration System registry. Data were reported in aggregate, trends over time were assessed using linear regression models, and differences by gender were analyzed using the Wilcoxon rank sum test. Results Over the 6-year time period from 2014 to 2019, a total of 1,610,668 payments totaling $221,254,966 were made to 5,723 rheumatologists. The median payment was $15 (interquartile range [IQR] $10 to $22), and the median total amount received by individual rheumatologists over the 6-year period was $2,818 (IQR $464 to $11,560). The majority of rheumatologists (3,416 of 5,723 [60%]) received less than $5,000, but 368 of 5,723 (6%) received more than $100,000 each and accounted for 78% of the total. The yearly value of payments increased over time ($3,703,264 per year; P < 0.001), and the median payment to male rheumatologists was significantly higher than the median payment to female rheumatologists ($3,723 [IQR $542 to $15,841] versus $2,084 [IQR $394 to $8,186]; P < 0.001). Conclusion The value of industry payments has increased over time, and a large amount is concentrated among a small number of rheumatologists. Future studies should investigate the degree to which industry payments have influenced prescribing in the field of rheumatology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Rheumatology

Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance

Manuel Francisco Ugarte-Gil, Graciela S. Alarcon, Zara Izadi, Ali Duarte-Garcia, Cristina Reategui-Sokolova, Ann Elaine Clarke, Leanna Wise, Guillermo J. Pons-Estel, Maria Jose Santos, Sasha Bernatsky, Sandra Lucia Euzebio Ribeiro, Samar Al Emadi, Jeffrey A. Sparks, Tiffany Y-T Hsu, Naomi J. Patel, Emily L. Gilbert, Maria O. Valenzuela-Almada, Andreas Jonsen, Gianpiero Landolfi, Micaela Fredi, Tiphaine Goulenok, Mathilde Devaux, Xavier Mariette, Viviane Queyrel, Vasco C. Romao, Graca Sequeira, Rebecca Hasseli, Bimba Hoyer, Reinhard E. Voll, Christof Specker, Roberto Baez, Vanessa Castro-Coello, Hernan Maldonado Ficco, Edgard Torres Reis Neto, Gilda Aparecida Aparecida Ferreira, Odirlei Andre Andre Monticielo, Emily Sirotich, Jean Liew, Jonathan Hausmann, Paul Sufka, Rebecca Grainger, Suleman Bhana, Wendy Costello, Zachary S. Wallace, Lindsay Jacobsohn, Tiffany Taylor, Clairissa Ja, Anja Strangfeld, Elsa F. Mateus, Kimme L. Hyrich, Loreto Carmona, Saskia Lawson-Tovey, Lianne Kearsley-Fleet, Martin Schaefer, Pedro M. Machado, Philip C. Robinson, Milena Gianfrancesco, Jinoos Yazdany

Summary: The severity of COVID-19 outcomes in individuals with SLE is associated with factors such as gender, age, steroid dosage, comorbidities, and the activity of SLE.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Article Rheumatology

Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study

Matthew J. Koster, Cynthia S. Crowson, Rachel E. Giblon, Jane M. Jaquith, Ali Duarte-Garcia, Eric L. Matteson, Cornelia M. Weyand, Kenneth J. Warrington

Summary: This study investigated the use of baricitinib in patients with relapsing giant cell arteritis (GCA) and found it was well tolerated, allowing for discontinued use of glucocorticoids in most patients. Larger randomized clinical trials are necessary to further evaluate the efficacy of JAK inhibition in GCA.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Article Medicine, General & Internal

Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology

Ali Duarte-Garcia, Cynthia S. Crowson, Rozalina G. McCoy, Jeph Herrin, Veronica Lam, Michael S. Putman, Joseph S. Ross, Eric L. Matteson, Nilay D. Shah

Summary: Payments from pharmaceutical companies to rheumatologists are associated with increased probability of prescribing and Medicare spending.

MAYO CLINIC PROCEEDINGS (2022)

Article Rheumatology

Population-based incidence and time to classification of systemic lupus erythematosus by three different classification criteria: a Lupus Midwest Network (LUMEN) study

Ali Duarte-Garcia, Mehmet Hocaoglu, Shirley-Ann Osei-Onomah, Jesse Y. Dabit, Rachel E. Giblon, Charles G. Helmick, Cynthia S. Crowson

Summary: The study found that the incidence of SLE was higher when classified by the EULAR/ACR criteria compared to the ACR97 and SLICC criteria. The EULAR/ACR criteria also classified patients earlier than the ACR97 criteria, but similarly to the SLICC criteria.

RHEUMATOLOGY (2022)

Article Rheumatology

Risk of hydroxychloroquine retinopathy in the community

Jesse Y. Dabit, Mehmet Hocaoglu, Kevin G. Moder, Andrew J. Barkmeier, Wendy M. Smith, Thomas J. O'Byrne, Cynthia S. Crowson, Ali Duarte-Garcia

Summary: This study aimed to estimate the risk of HCQ retinopathy among incident users in the community. HCQ retinopathy risk at 10 years of use was found to be lower compared to previous estimations, with a significant increase in risk associated with higher doses and cumulative doses of HCQ. Aim for HCQ dose control at <5 mg/kg to reduce the risk of retinopathy.

RHEUMATOLOGY (2022)

Article Rheumatology

Epidemiology of Childhood-Onset Systemic Lupus Erythematosus: A Population-Based Study

Maria O. Valenzuela-Almada, Mehmet Hocaoglu, Jesse Y. Dabit, Shirley-Ann Osei-Onomah, Matthew L. Basiaga, Amir B. Orandi, Rachel E. Giblon, Kamil E. Barbour, Cynthia S. Crowson, Ali Duarte-Garcia

Summary: This study characterized the incidence and prevalence of childhood-onset systemic lupus erythematosus (SLE) and found that the diagnosis rate of SLE in childhood was around 9% among all SLE patients. Further studies are needed to understand the epidemiology of childhood-onset SLE in minority populations.

ARTHRITIS CARE & RESEARCH (2022)

Review Rheumatology

SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta-analysis

Richard Conway, Alyssa A. Grimshaw, Maximilian F. Konig, Michael Putman, Ali Duarte-Garcia, Leslie Yingzhijie Tseng, Diego M. Cabrera, Yu Pei Eugenia Chock, Huseyin Berk Degirmenci, Eimear Duff, Bugra Han Egeli, Elizabeth R. Graef, Akash Gupta, Patricia Harkins, Bimba F. Hoyer, Arundathi Jayatilleke, Shangyi Jin, Christopher Kasia, Aneka Khilnani, Adam Kilian, Alfred H. J. Kim, Chung Mun Alice Lin, Candice Low, Laurie Proulx, Sebastian E. Sattui, Namrata Singh, Jeffrey A. Sparks, Herman Tam, Manuel F. Ugarte-Gil, Natasha Ung, Kaicheng Wang, Leanna M. Wise, Ziyi Yang, Kristen J. Young, Jean W. Liew, Rebecca Grainger, Zachary S. Wallace, Evelyn Hsieh

Summary: This study indicates that individuals with rheumatic and musculoskeletal diseases (RMDs) have a higher risk of SARS-CoV-2 infection and an increased mortality rate compared to those without RMDs.

ARTHRITIS & RHEUMATOLOGY (2022)

Editorial Material Rheumatology

Cardiovascular Disease Disparities in Systemic Lupus Erythematosus

Ali Duarte-Garcia, Jinoos Yazdany

JOURNAL OF RHEUMATOLOGY (2023)

Article Rheumatology

Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the COVID-19 Global Rheumatology Alliance

Manuel F. Ugarte-Gil, Graciela S. Alarcon, Andrea M. Seet, Zara Izadi, Anna D. Montgomery, Ali Duarte-Garcia, Emily L. Gilbert, Maria O. Valenzuela-Almada, Leanna Wise, Jeffrey A. Sparks, Tiffany Y. -T. Hsu, Kristin M. D'Silva, Naomi J. Patel, Emily Sirotich, Jean W. Liew, Jonathan S. Hausmann, Paul Sufka, Rebecca Grainger, Suleman Bhana, Zachary Wallace, Lindsay Jacobsohn, Anja Strangfeld, Elsa F. Mateus, Kimme L. Hyrich, Laure Gossec, Loreto Carmona, Saskia Lawson-Tovey, Lianne Kearsley-Fleet, Martin Schaefer, Pedro M. Machado, Philip C. Robinson, Milena Gianfrancesco, Jinoos Yazdany

Summary: A study on individuals with SLE in the US found that Black and Hispanic patients had higher odds of experiencing more severe COVID-19 outcomes compared to White patients, which may be attributed to socioeconomic and health disparities.

ARTHRITIS CARE & RESEARCH (2023)

Article Rheumatology

Supporting International Medical Graduates in Rheumatology: A Call to Action

Ruth Fernandez-Ruiz, Ali Duarte-Garcia, Noelle A. Rolle, Sebastian E. Sattui, Didem Saygin, Sharon Dowell, Swetha A. Alexander, Bharat Kumar, Maria Danila, Namrata Singh

ARTHRITIS & RHEUMATOLOGY (2023)

Article Rheumatology

Unpublished clinical trials of common rheumatic diseases

Connor Pedersen, Shannon Tai, Erin Valley, Kathryn Henry, Ali Duarte-Garcia, Shikha Singla, Michael Putman

Summary: This study aims to describe the proportion of unpublished randomized controlled trials (RCTs) in rheumatic diseases and identify factors associated with publication. Results showed that a high proportion of published trials were phase 3 RCTs (57.1% vs 28.6% unpublished) or had a positive primary outcome (64.9% vs 25.7% unpublished). This highlights the issue of unpublished RCTs in rheumatology and the association between publication and positive outcomes.

RHEUMATOLOGY (2023)

Review Rheumatology

Development of American College of Rheumatology Quality Measures for Systemic Lupus Erythematosus: A Modified Delphi Process With Rheumatology Informatics System for Effectiveness (RISE) Registry Data Review

Christie M. Bartels, April Jorge, Candace H. Feldman, JoAnn Zell, Bonnie Bermas, Claire E. H. Barber, Ali Duarte-Garcia, Shivani Garg, Leah Haseley, Shraddha Jatwani, Tracy Johansson, Alex Limanni, Wendy Rodgers, Brad H. Rovin, Yesenia Santiago-Casas, Lisa G. Suter, April Barnado, Jennifer Ude, Alfredo Aguirre, Jing Li, Gabriela Schmajuk, Jinoos Yazdany

Summary: This study aimed to develop measurable digital quality measure statements for clinical care in systemic lupus erythematosus (SLE) using a consensus method. A panel of SLE experts reviewed guidelines and extracted quality constructs to generate evidence-based quality measure statements. Through a Delphi process, three top-ranked statements on hydroxychloroquine use, glucocorticoid reduction, and kidney monitoring were selected for further specification and testing.

ARTHRITIS CARE & RESEARCH (2023)

Article Rheumatology

Disparities in multimorbidity and comorbidities in rheumatoid arthritis by sex across the lifespan

Maria A. Stevens, Hayley J. Dykhoff, Vanessa L. Kronzer, Elena Myasoedova, John M. Davis, Ali Duarte-Garcia, Cynthia S. Crowson

Summary: Multimorbidity has a greater impact on women with RA, while men are more likely to have cardiovascular-related conditions. These findings suggest that research, clinical practice, and policies related to rheumatic diseases should take into account the variation in care needs by sex and gender.

RHEUMATOLOGY (2023)

Article Rheumatology

Multimorbidity in systemic lupus erythematosus in a population-based cohort: the Lupus Midwest Network

Gabriel Figueroa-Parra, Jose A. Meade-Aguilar, Cassondra A. Hulshizer, Tina M. Gunderson, Alanna M. Chamberlain, Uma Thanarajasingam, Kurt J. Greenlund, Kamil E. Barbour, Cynthia S. Crowson, Ali Duarte-Garcia

Summary: The study aimed to assess the prevalence and incidence of multimorbidity and its association with the SLICC/ACR damage index (SDI) among patients with SLE. The results showed that patients with SLE were more likely to have multimorbidity, both before and after the onset of the disease. Multimorbidity was driven by both SDI-related and unrelated conditions.

RHEUMATOLOGY (2023)

Article Rheumatology

Comparative Efficacy Randomized Controlled Trials in Rheumatology Guidelines

Katie Henry, Desh Nepal, Erin Valley, Connor Pedersen, Ali Duarte-Garcia, Michael Putman

Summary: This study examined the impact of comparative efficacy randomized controlled trials (RCTs) on rheumatology guidelines and found that their influence is relatively low. The majority of cited RCTs evaluated biologic/targeted synthetic disease-modifying antirheumatic drugs, with a minority using a head-to-head design. Only a small percentage of recommendations had a high level of evidence support.

ACR OPEN RHEUMATOLOGY (2022)

No Data Available